This is according to results from the largest study to date, presented to the European Cancer Congress 2017 yesterday, 30 January.
Almost 130 000 breast cancer patients studied
Researchers studied survival in nearly 130 000 breast cancer patients nationwide in the Netherlands.
The patients were divided into two groups: those diagnosed between 1999 and 2005 and those diagnosed between 2006 and 2012 and had no metastases (spread of the cancer to organs other than the lymph nodes close to the tumour).
Who benefits from breast conserving therapy?
The study showed a considerable advantage for BCT in mature patients, those with comorbidity, and those who did not receive chemotherapy.
The research team believe this information could improve treatment decision-making for future breast cancer patients over 50.
